Changchun High-tech: The application for clinical trials in China for the subsidiary GenSci148 injection has been approved.

Changchun Gaoxin announced that recently, its subsidiary Gensai Pharmaceutical received approval from the National Medical Products Administration for the issuance of the "Notice of Approval for Drug Clinical Trials." The clinical trial application for the domestic production of GenSci148 injection has been approved, with indications for neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. This injection is a VEGF multi-blocker independently developed by Gensai Pharmaceutical, which is expected to provide better treatment options for related patients. However, there is uncertainty regarding the subsequent progress and results of the clinical trial.